HIV-infected children represent an incredibly diverse group of patients, ranging from neonates to young adults. With the change in age and maturity, paediatric highly active antiretroviral therapy (HAART) evolves from the meticulous twice-daily dosing of ml of liquid preparations to a choice of once-daily dosing of a single fixed-dose coformulated tablet. The use of simplified paediatric regimens could enhance the ability to achieve successful implementation of HAART in HIV- infected children. Pharmacokinetics and pharmacodynamic studies of antiretroviral drugs and their combinations need to be conducted in infants, children and adolescents to develop appropriate dosing in each of these specific groups.
References
1.
Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children.Guidelines for the use of antiretroviral agents in pediatric HIV infection. (Updated 23 February 2009. Accessed 21 October 2009.) Available from http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.
2.
PENTA Steering Committee.PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.HIV Med2009; 10: 591–613.
3.
World Health Organization.Preferred antiretroviral medicines for treating and preventing HIV infection in younger children: report of the WHO Paediatric Antiretroviral Working Group 2008. (Updated 20 May 2008. Accessed 20 October 2009.) Available from http://www.who.int/hiv/pub/paediatric/ARV_WG_meeting_report_may2008.pdf.
4.
Committee on Pediatric AIDS, Section on International Child Health.Increasing antiretroviral drug access for children with HIV infection.Pediatrics2007; 119: 838–845.
5.
GoodeM., McMaughA., CrispJ.Adherence issues in children and adolescents receiving highly active antiretroviral therapy.AIDS Care2003; 15: 403–408.
6.
Van DykeR.B., LeeS., JohnsonG.M.Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.Pediatrics2002; 109: e61.
7.
WinnickS., LucasD.O., HartmanA.L.How do you improve compliance?Pediatrics2005; 115: e718–e724.
8.
MoyleG.J., DeJesusE., CahnP.Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.J Acquir Immune Defic Syndr2005; 38: 417–425.
9.
LePrevostM., GreenH., FlynnJ.Adherence and acceptability of once daily lamivudine and abacavir in human immunodeficiency virus type-1 infected children.Pediatr Infect Dis J2006; 25: 533–537.
10.
MolinaJ.M.Efficacy and safety of once-daily regimens in the treatment of HIV infection.Drugs2008; 68: 567–578.
11.
ParientiJ.J., BangsbergD.R., VerdonR.Better adherence with once-daily antiretroviral regimens: a meta-analysis.Clin Infect Dis2009; 48: 484–488.
12.
McKinneyR.E.Jr., RodmanJ., HuC.Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.Pediatrics2007; 120: e416–e423.
13.
ScherpbierH.J., BekkerV., PajkrtD.Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.Pediatrics2007; 119: e705–e715.
14.
BergshoeffA., BurgerD., VerweijC.Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).Antivir Ther2005; 10: 239–246.
15.
PENTA. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3–<36 months.Antiviral Therapy2010; 15: 297–305.
16.
BlaschkeT.F.Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes.Curr Opin HIV AIDS2008; 3: 603–607.
17.
RossoR., Di BiagioA., DentoneC.Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.J Antimicrob Chemother2006; 57: 1168–1171.
18.
van der LeeM., VerweelG., de GrootR.Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.Antivir Ther2006; 11: 439–445.
19.
van der FlierM., VerweelG., van der KnaapL.C.Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.Antivir Ther2008; 13: 1087–1090.
20.
la PorteC., van HeeswijkR., MitchellC.D.Pharmacokinetics and tolerability of once- versus twice- daily lopinavir/ritonavir treatment in HIV-1-infected children.Antivir Ther2009; 14: 603–606.
L'HommeR.F., KabambaD., EwingsF.M.Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.AIDS2008; 22: 557–565.
